

NB: this is a summary translation of the press release
original drafted in Japanese for the disclosure
required in compliance with the TSE regulations.

March 22, 2021

Oncolys BioPharma Inc.

Announcement of GMP manufacturing of investigational product of OBP-2011 for the treatment of COVID-19

Oncolys BioPharma Inc. (hereafter, “Oncolys”) today announced that Oncolys and Iwaki Seiyaku Co., Ltd. (hereafter, “Iwaki Seiyaku”) have agreed to memorandum of understanding (hereinafter, “MOU”) for GMP manufacturing of active pharmaceutical ingredient of OBP-2011, a novel COVID-19 drug candidate.

The both companies will further conclude Contract Manufacturing Agreement, and Iwaki Seiyaku will conduct GMP compliant manufacturing of OBP-2011 drug substance. Oncolys will receive the drug substance from Iwaki Seiyaku in the first quarter of 2021. After completion of manufacturing the investigational product of OBP-2011. Oncolys will initiate a clinical trial after IND approval in 2022.

As Oncolys announced on March 8, 2021, Oncolys develops OBP-2011 as a result of screening various analog compounds. OBP-2011 showed that the drug is orally available and has no meaningful toxicity in pre-clinical studies.

*The financial effect of the above will be minor for the fiscal year ending December 31, 2021.

Ends

###

About Oncolys BioPharma Inc.

Oncolys BioPharma develops not only novel therapeutics for cancer and serious infectious diseases, but diagnostic products using gene modified viral technologies and aims to contribute to fulfill unmet medical needs for those diseases.

Especially in oncology area, we utilize technology platform for oncolytic virus and develop Telomelysin and its next-generations for cancer treatment and TelomeScan for early detection of cancer and recurrence monitoring after surgery. We have established broad range of product pipeline to cover early detection of cancer, early treatment of local cancer, post-operative examination, and treatment of metastatic cancer. For more information, please visit <http://www.oncolys.com/en/>

Oncolys BioPharma Inc.

Email: oncolys_information@oncolys.com